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Abstract 
Background: An increased risk of impaired intelligence (IQ) has been documented in 
valproate-exposed children, but investigations have not previously focused on those 
with a clinical diagnosis of Fetal Valproate Syndrome (FVS).  
Methods: This cross sectional observational study recruited individuals with a 
diagnosis of FVS and completed standardized assessments of intellectual abilities 
making comparisons to a normative comparison group.  Both mean difference (MD) 
and prevalence of scores below the lower average range were analyzed.   
Results: The mean full-scale IQ in 31 individuals with FVS (mean age 14.97; range 
6-27 years) was 19 points lower (19.55, 95% CI -24.94 to 14.15), and IQ scores <70 
were present in 26%. The mean differences for verbal comprehension (21, 95% CI -
25.84 to -16.29), working memory (19.77, 95% CI -25.00 to -14.55) and processing 
speed (16.87, 95% CI -22.24 to -11.50) performances were poorer than expected 
with the mean differences over one standard deviation from the comparison group. 
Sixty one percent of cases demonstrated disproportionately lower verbal 
comprehension ability. There were no significant group differences for IQ in high vs. 
moderate dose valproate or mono vs. polytherapy. There were no differences in IQ 
between those with and those without a major congenital malformation. The 
requirement for educational intervention was high at 74%.  
Conclusion: Intellectual difficulties are a central feature of fetal valproate syndrome 
and are more severe in their presentation in individuals with a diagnosis of valproate 
embryopathy. Individuals with Fetal Valproate Syndrome who present with the 
characteristic facial presentation should be considered at high risk of difficulties 
regardless of the dose of valproate exposure or the presence of a major congenital 
malformation.  
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1. Introduction  
Prenatal exposure to valproate is associated with an increased risk of 
neurodevelopmental deficits(1) in addition to the association with congenital 
malformations(2). Fetal valproate syndrome (FVS) is diagnosed when an individual 
has a recognizable pattern of facial features, specific malformations, medical or 
developmental problems in the context of in utero exposure to valproate and 
following exclusion of other conditions(3). Early reports specifically describing 
individuals with clinically confirmed FVS frequently documented neurodevelopmental 
deficits(4-6) but, to date, there has been only one cohort study of children with  FVS(7). 
Thirty four children with FVS were reviewed, and elevated rates of developmental, 
speech and motor delay, along with a high rate of educational support requirements 
were found(7). However, reports of delay were based on parental report and no 
objective standardized intellectual assessment was undertaken in this cohort, so the 
sensitivity to detect intellectual impairment was limited.  
 
There have been a number of studies aimed at investigating the risk to child 
cognitive functioning following exposure in the womb to valproate,(1) and such 
studies have clearly demonstrated that prenatal exposure to valproate is associated 
with an increased risk of poorer cognitive functioning; including poorer levels of early 
development(8,9,10), intellectual abilities(11-15), increased need for educational 
support(12,16), poorer educational examination results,(17) and increased rates of 
autistic spectrum disorder. These cohorts, however, include children with a general 
history of valproate exposure and are not confined to children with confirmed 
valproate embryopathy based on clinical review and following the exclusion of other 
likely causes of the child’s difficulties. Individuals with FVS represent a specific group 
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in whom a distinct cognitive profile may occur, and there remains then a lack of data 
pertaining to the intellectual abilities of individuals with clinically confirmed FVS. 
Considering that 30-40% of children with a history of valproate had an IQ one 
standard deviation below the mean(1), individuals with FVS are undoubtedly at risk 
for intellectual difficulties, but the pattern, severity, and prevalence of such deficits 
remain unknown. Recently, the risks to the fetus associated with valproate have 
been the subject of a European regulatory review(18) and are currently the subject of 
a government review in the UK.(19) It is therefore of paramount importance that 
information on the cognitive skills, including the intellectual abilities, of children with a 
clinical diagnosis of FVS.  
 
The objective of this study was to collect information on the cognitive skills of 
individuals with a clinically confirmed diagnosis of FVS. It was hypothesized here 
that individuals with FVS would have a more severe level of intellectual difficulties 
than rates previously obtained from the cohorts of children with a history of valproate 
exposure whereby some in the group may exhibit morphological effects whilst others 
appear to be unaffected with respect to facial and other features 
 
2. Methodology 
2.1. Recruitment 
Children and adults with a diagnosis of FVS were recruited from one of two sources: 
the Manchester University NHS Foundation Trust’s Genomic Medicine Department 
and from two UK based charities who support families post-diagnosis of FVS 
(Organization for Anti-convulsant Syndrome and The Fetal Anti-convulsant Trust). 
Letters were sent to patients of the Genomic Medicine department who were 
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diagnosed with FVS inviting them to participate (46% recruitment rate). Those 
recruited through the charities were self-selecting following advertisements regarding 
the study. In the UK, the diagnosis of FVS is made based on previously published 
guidance whereby the following criteria should be met(3): 1) a history of in utero 
exposure, 2) presence of a characteristic facial appearance, 3) presence of at least 
one of the following: evidence of neonatal withdrawal, compatible congenital 
malformation, compatible medical problem, compatible developmental history, 
compatible behavioral problem, 4) normal relevant genetic investigations. Children 
and adults who were unable to provide written consent gave written assent with their 
parents providing written permission for participation. In families where there was 
more than one child with FVS, the oldest child was recruited into the study.  
 
2.2. Assessment  
Participants were assessed either in their home or at the University of Birmingham’s 
Imaging Centre. Background history was from maternal report on medication type, 
dose and developmental and educational history. In the cases recruited from the 
hospital, medical notes were consulted, where available, and in cases recruited 
through charities, available letters from medical specialists were reviewed to verify 
the diagnosis of FVS.  
 
Individuals with FVS under the age of 16 years, 11 months and 30 days (n=18) were 
assessed with the Wechsler Intelligence Scale for Children, 4th edition (WISC-IV)(20); 
with those older (n=13) completing the Wechsler Adult Intelligence Scale, 4th Edition 
(WAIS-IV)(21). The test publishers reported an equivalence study on 157 examinees 
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and reported high levels of correlation across the two measures (ranging from 0.77 
to 0.91)(20,21).  
 
Subtest scaled scores on the Wechsler Intelligence Scales were grouped into the 
domains of full-scale IQ, verbal comprehension index, perceptual reasoning index, 
working memory index, and processing speed index. Where the same subtest was 
present on both the adult and child measure, results were pooled to give a single 
mean score. Discrepancies between the test index scores were calculated in line 
with the appropriate test manual by age of the participant and based on the overall 
sample(20,21). The significance level for discrepancies between the index scores was 
set at the 0.05 level. A discrepancy between two index scores may reach 
significance but may still be relatively frequent in the normative population, and 
therefore, the level of discrepancy was only classed as ‘clinically significant’ here if it 
exceeded the discrepancy amount obtained by equal or fewer than 5% of the 
normative comparison group. Classification of scores was undertaken in line with the 
published guidance (20,21): scores below 80 classified as below the lower average 
range. Additionally, the prevalence of individuals with scores over one standard 
deviation from the mean was also computed to allow for comparison to previous 
reports.  
 
Data were collected on key covariates including maternal IQ, which was assessed 
using the two-subtest version of the Wechsler Abbreviated Intelligence Scale 
(WASI)(22). Information on gestational age at birth, presence of malformations, and 
dose of valproate were taken from maternal report and consultant letters, where 
available, and were included along with other covariates (gender, age at assessment 
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and handedness).  Assessments were completed by authors RB and AW, all 
assessments were double scored, and both verbal and written feedback was 
provided to the families. In a number of cases, feedback was provided to schools at 
the family’s request.  
 
2.3. Comparator group 
We were unable to utilize an unexposed comparison group due to constraints of this 
study and instead, we used the normative data provided in the Wechsler IQ tests for 
comparison. Both the WISC-IV and WAIS-IV have large normative populations that 
are reported to be representative of the U.S English speaking population and are 
stratified by age, gender, ethnicity, education level, and geographical region(20,21). 
The normative population mean across both measures is 100 with a standard 
deviation of 15 for index scores and have a mean of 10 with a standard deviation of 
3 at the subtest level.  
 
2.4. Analysis 
Data was entered and statistics produced in SPSS version 22.  Due to the number of 
comparisons made at both the index and subtest levels, a Bonferroni correction was 
applied, and significance was set at <0.003 (0.05/18). Univariate linear regression 
was used to investigate the influence on the IQ indexes of the following variables: 
gender, polytherapy, valproate dose, maternal IQ, age at assessment, handedness, 
and IQ test. Variables with a p value of <0.2 were entered into multiple regression 
analysis. To investigate dose of valproate, the group was split into doses <1500 
mg/d (moderate dose group) or >1500 mg/d (high dose group), which was the dose 
closest to the median for the group (1650 mg/d). When the mother reported 
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increasing dose during gestation, the highest dose was utilized in the dose 
assessments reported below. 
 
2.5. Ethical approval  
Ethical approval was provided by North West Regional Ethics Committee- 
Manchester Central (Reference 12/NW/0221) and Central Manchester University 
Hospitals NHS Foundation Trust.  
 
3. Results  
Recruitment totaled 34 participants, however one child was unable to be assessed 
due to significant challenging behavior, one participant was excluded due to a 
diagnosis of spina bifida with hydrocephalus, and in one case a definite diagnosis of 
FVS could not be ascertained.  
 
In all cases, use of valproate was for the treatment of epilepsy, and in all cases 
exposure lasted for the entire gestational period. The valproate exposure was 
monotherapy in 22 cases (71%), with eight additional cases exposed to one 
additional AED concurrently (carbamazepine n=2, lamotrigine n=2, phenytoin n=1 
and clobazam n=2) and in one case to two additional AEDs (carbamazepine and 
vigabatrin). The mean dose of valproate for maternal treatment was 1650 mg/d 
(1676 mg/d for monotherapy exposures and 1711 mg/d for polytherapy). Further 
details regarding cohort characteristics are displayed in Table 1. 
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3.1. Intellectual function: Index scores 
 
Analysis of the neuropsychological data was therefore conducted on IQ data for 31 
individuals with FVS (aged 6 to 27 years). No significant differences in terms of 
intellectual outcome were found between those completing the adult or child IQ 
assessments (mean difference -5.45 95% CI -16.3 to 5.4, p=.317), and therefore, the 
cohort was treated as a single group. Across all the assessed skill areas, there were 
no significant differences between monotherapy and polytherapy cases or between 
those who were attributed to the high dose group and those in the moderate dose 
group (Table 2).  
 
The mean full-scale IQ score was 19 points lower for those with FVS (-19.55, 95% CI 
-24.94 to -14.15) (Table 3), with 15/31 (52%) falling below the average range (Figure 
1). The rate of individuals with a IQ <70 was 8/31 (26%).  Individuals with FVS 
scored significantly lower on the verbal comprehension index with a mean difference 
(MD) of -21 points (95% CI -25.84 to -16.29). Of note, 7/31 of the FVS sample 
scored <70 (23%) (Figure 1) and the rate of performance one standard deviation 
below the mean was 19/31 (61%). The FVS group also performed poorer on the 
working memory index (-19.77, 95% CI -25.00 to -14.55) and the processing speed 
index (-16.87, 95% CI -22.24 to -11.50), with elevated scores below the lower 
average ranges (Figure 1). The perceptual reasoning index was the only index in 
which the FVS group means did not differ (Table 3), and where there were more 
comparable rates of performance falling within the extremely low range (3/31, 7%).  
 
3.2. Intellectual function: Subtest performance  
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Reductions in performance on verbal tasks were seen across nearly all verbal 
subtests and therefore the verbal comprehension index weakness was not being 
driven by one isolated deficit (Table 3).  
 
3.3. Index discrepancies  
 
Significant levels of individual performance discrepancy were noted between the 
verbal comprehension index and the perceptual reasoning index; with 19 cases 
(61%) demonstrating a significantly poorer verbal comprehension index. Two 
additional cases showed levels of discrepancy within one point of the threshold 
required for a classification of a significant discrepancy. Only 1 case (3%) 
demonstrated a significant discrepancy in the other direction (perceptual reasoning < 
verbal comprehension) but not to a clinically significant level. Within those with 
significantly poorer verbal comprehension score, 12/31 (38%) had a clinically 
significant level of discrepancy; the level found in only 5% of the comparison group. 
Other discrepancy comparisons are reported in eTable/supplementary 1. 
 
3.4. Factors associated with an increase in reduced IQ 
 
Subsidiary analyses were used to examine factors associated with IQ. Univariate 
regression analysis failed to find an association between polytherapy valproate 
exposure or dose of valproate (as a continuous variable) with any of the index 
scores, even when the influence of maternal IQ was adjusted for. The IQs of 21 of 
the mothers (68%, mean= 103) were available; none scored below <70; 15/31 (48%) 
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and 4/31 (13%) were in the average and above average range, respectively. There 
were no differences in offspring IQ for families in which we did/not have maternal IQ 
data (FSIQ, U= 87.50, Z -1.112, p=2.71). The variables of gender, age at 
assessment, IQ test type, and handedness were all found to have p values <0.2 in 
their respective univariate analyses for one or more of the indexes; however the 
multiple linear regression models found no significant association between these 
variables and the index scores (ETable 2).  
 
3.5. Educational outcome 
Seventy four percent of participants were reported to require formal learning support 
either within a mainstream educational setting or in a special school environment. Of 
those who required educational support 14/31 (61%) had a full scale IQ and a verbal 
comprehension index below the average range (IQ<80).  
  
4. Discussion  
 
Formal assessment of intellectual abilities in individuals with FVS revealed high rates 
of poorer performance and increased rates of IQ <70, which were driven by poor 
verbal comprehension/reasoning, auditory working memory, and processing speed 
deficits. This is the first study to report on a cohort of individuals with clinically 
diagnosed FVS. The findings are concordant with the larger observational studies of 
children with a history of valproate exposure but highlight the more severe 
presentation of the intellectual difficulties in children diagnosed with FVS. 
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Verbal comprehension ability was the weakest skill for the individuals with FVS, and 
analysis of the subtests demonstrated wide ranging verbal cognition deficits. Weaker 
verbal reasoning/IQ skills have been frequently reported within cohorts of children 
exposed to valproate(1,11-15) but not to the level reported here.  Deficits in purer 
language functioning have also been reported(14) and, neuroarchitecture in eloquent 
cortex has been reported to be abnormal in children with a history of valproate 
exposure(23). The results here are consistent with previous findings but suggest that 
the severity of the cognitive difficulties is increased in those with diagnosed FVS. 
Fifty two percent of those with FVS had a verbal comprehension score below 
average which is only present in 9% of the normative sample of the Wechsler 
measure. High levels of discrepancy between individual performances on the verbal 
comprehension index and the perceptual reasoning index suggest that this 
discrepancy is a frequent feature within the FVS phenotype. The question as to why 
verbally mediated skills are disproportionally affected by valproate exposure requires 
further investigation. 
 
The cohort also displayed reduced performance in their auditory working memory 
abilities, and 38% demonstrating impairment in both their verbal comprehension and 
auditory working memory ability. Difficulties with processing of visual information 
were also noted to significant levels with over half falling below the average range. 
Observations of this cohort during completion of the assessments supported these 
findings with assessments taking longer than is standard to complete. The 
substantial need for educational support (74%) was identical to that reported 
previously(7) and demonstrates the real life implications of the reported IQ deficits 
and the cost not only to the individual but also to society.  
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The presence of a major congenital malformation has been associated with a 
significantly increased chance of lower IQ in the context of valproate exposure(12); 
however, we demonstrated here that intellectual difficulties were not confind to those 
with a major congenital malformation. This has been highlighted by others (14,24), and 
suggests that intellectual difficulties are not simply predicted by the presence of a 
major congenital malformation following valproate exposure. All participants in this 
study demonstrated more subtle physical markers of exposure (i.e. dysmorphic facial 
features) as these are required to be present to reach the diagnostic criteria for 
FVS(3). Previous work highlighted a relationship between dysmorphic facial features 
consistent with valproate exposure and child IQ(25). This study provides additional 
evidence to support the diagnostic criteria of Dean et al(3) that a diagnosis of fetal 
valproate syndrome should be considered, even in the absence of a major 
congenital malformation, should the typical facial and neurodevelopmental features 
be present.  
 
Rates of IQ one standard deviation below the mean were higher at 61% and 54% for 
the verbal comprehension index and the FSIQ respectively, than the 30-40% figures 
reported from groups of children with valproate exposure(1) but without confirmed 
FVS. Further, the effect sizes noted for the FSIQ and verbal comprehension index 
are substantially higher than those reported from general valproate exposure 
cohorts(1-16). This is hypothesized to be due to two co-existing factors. The mean 
dose in this cohort was higher. Secondly, this group, through their physical 
symptoms, had been demonstrated to be susceptible to the associated effects of the 
valproate exposure.  This highlights the likelihood that there exists a spectrum of 
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deficits associated with prenatal valproate exposure, and that there is a need to 
accurately characterize the breadth of this spectrum but also the specific features of 
different presentations as we have begun to do here. This study has demonstrated 
that extrapolating rates of intellectual difficulties from a cohort of children with a 
history of valproate exposure(12,14,15) to summarise the intellectual difficulties of 
children with confirmed valproate embryopathy would not reliable. More research 
attention should be directed to a better understanding of the full impact of valproate 
exposure, and the specific characteristics of children with confirmed valproate 
embryopathy. 
 
 
This study has many strengths. It is the first study to systematically measure the 
profile of intellectual function in this particular condition and highlights the significant 
burden on the individuals and their families and the cost to society. Unlike previously 
published cohorts of valproate exposed children, this group was limited to individuals 
with a confirmed diagnosis of FVS, other possible causes of their difficulties had 
been discounted and they presented with the physical symptoms of valproate 
exposure. The use of standardized intelligence assessments provided increased 
rigor in the measurement of cognitive functioning. The inclusion of one child per 
family removed the risk of sibling confounding/bias, and the exclusion of cases with a 
condition with a known association with neurodevelopmental difficulties removed 
further possible biases. Finally, the inclusion of adults with the condition provided the 
first evidence that the cognitive deficits associated with FVS do not diminish over 
time. These important data will allow for accurate counseling of families at diagnosis 
and for the planning of future needs. 
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The study had some limitations. The measurement of maternal IQ was only 
completed in 68% of cases where the mother was in attendance at the appointment. 
Although incomplete, the spread of maternal IQ results indicated that the IQ results 
presented here for the individuals with FVS are not simply due to lower maternal IQ; 
a lack of relationship between maternal and child IQ following exposure to valproate 
is consistent with the findings of others(10). Weaker aspects of this study design 
include its opportunistic sampling method which may have introduced bias towards 
the more severely affected individuals with FVS; however, the pattern of intellectual 
difficulty reflects that reported from prospectively ascertained cohort studies of 
children with a history of valproate exposure. Further, the authors have significant 
experience with FVS, and these results reflect anecdotal clinical experience. History 
of the mother and the individual with FVS was taken from maternal report and the 
medical notes or specialist clinic letters provided by the families and therefore may 
be influenced by recall bias. Data pertaining to consumption of other teratogens 
(such as alcohol or nicotine) was not documented in the current protocol as this 
cohort had been clinically diagnosed with valproate emybryopathy, and there were 
substantial concerns regarding recall bias due to the length of time passed. 
Nevertheless, their clinical diagnosis supports the contention that the intellectual 
features described cannot be attributed to other teratogen exposures, and we have 
included in our analysis other potential confounds. Future studies should extend the 
finding with sequential case ascertainment, with increased amounts of prospectively 
ascertained information, additional details about the family background and with a 
control group recruited in the same manner.   
 
Conclusions 
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Intellectual difficulties within the FVS population are frequent, and it is therefore 
proposed that intellectual difficulties, particularly when there is a significant impact on 
verbal/auditory cognitive skills, should be considered a central feature of the FVS 
phenotype. The intellectual difficulties are likely lifelong. The dose of the valproate 
exposure and the absence of a major congenital malformation may not predict 
impact on IQ in a clinical population and if the individual has the facial characteristics 
of FVS a referral to an appropriate specialist for a neuropsychological assessment 
should be made.  
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Table 1. Fetal Valproate Syndrome (n=31) cohort characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Dose information was missing in 1 case.
2
 Malformation information was missing in 2 cases. Malformations 
included: Undescended testes (surgically corrected) 3 cases; Inguinal hernia (surgically corrected) 1 case; Right 
fibula and right toe missing;  Cleft hand; High palate ; Squint (surgical correction); Hypospadias (3 cases); Limb 
malformation; Narrow airway; Shoulder blade rotation; Radial ray defect; Congenital heart defect; Skeletal 
malformation (2 cases) ; Spina Bifida with Hydrocephalus.  
3 
Maternal IQ was missing in 10 cases.  
Key: N= number; mg/d = milligrams per day. 
 
 
 
 
  
 N  
 
Percentage Mean Range 
Valproate exposure  
 Monotherapy 22 71   
Polytherapy  9 29   
Dose
1
 30  1687 800-4500mg/d 
Education 
 Mainstream school – no 
support required 
8 26   
Statement of specialist 
educational needs 
23 74   
Gender  
 Male 18 58   
Female 13 42   
Handedness 
 Right 25 81   
Left  6 19   
Maternal IQ (points)
3
 21  103 70-127  
Malformations
2
 11 36   
Age at assessment (years) 31  15 6-27  
Mean FVS group FSIQ 31  80 56-108 
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Table 2: Mean IQ index scores by valproate exposure type, dose, malformation and 
assessment battery type. 
 
 
 
Key: SD standard deviation 
* equal variances not assumed due to sample difference between groups. 
^ malformation information was missing in two cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Index Verbal 
Comprehen
sion 
 
Perceptual 
Reasoning 
 
Working 
Memory 
 
Processing 
Speed 
 
Full Scale 
IQ 
 
Valproate Monotherapy 
(mean, SD) 
N=22 
77.68 (12.4) 91.82 (17.3) 79.32 (14.2) 84.91 (15.5) 79.64 (14.9) 
Valproate Polytherapy 
(mean, SD)  
N=9 
82.0 (14.7) 98.44 (18.2) 82.44 (14.8) 78.78 (12.0) 82.44 (15.0) 
High Valproate Dose 
(mean, SD) 
N=17 
80.12 (11.6) 92.12 (15.1) 76.94 
(13.43) 
81.29 (13.9) 79.00 (12.2) 
‘Moderate’ Valproate 
Dose (mean, SD) 
N=13 
77.23 (15.5) 94.54 (20.9) 83.23 (14.8) 86.08 (16.1) 81.62 (18.2) 
Major congenital 
malformation 
N=11 
76.45 (12.1) 92.18 (17.4) 
 
78.00 (12.3) 82.00 (13.6) 78.36 (13.0) 
No Major congenital 
malformation  
N=18^ 
79.00 (13.8) 93.50 (18.5) 80.17 (15.6) 83.28 (15.8) 80.33 (16.0) 
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Table 3. Differences in outcome mean IQ scores in comparison to the normative comparison 
mean.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 Indexes have a mean of 100 and a standard deviation of 15; subtests have a mean of 10 and standard 
deviation of 3. Subtests of Similarities, Vocabulary, Block Design, Matrix Reasoning, Digit Span, Coding, Symbol 
Search are present on both measures and therefore the mean score reflects the total cohort. Visual Puzzles, 
Arithmetic and Information are from the WAIS-IV only whilst the Letter Number Sequencing and Comprehension 
task are from those who completed the WISC only. 
2
 Mean adjusted for assessment type completed 
3
 FVS unadjusted mean in comparison to normative mean (100, standard deviation 15) 
 
Key: 95% CI = 95% confidence interval. 
 
 
  
Index/ Subtest
1
 FVS Mean
3
 
 
FVS Mean 
Adjusted
2
 
Mean difference 
(95% CI)
2
 
P value 
Verbal 
Comprehension 
78.94 79.44 -21.07 
(-25.84 to -16.29) 
t(30)=-9.004 
<0.0001 
 Similarities 6.61  -3.39  
(-4.27 to -2.50) 
 
 Vocabulary 5.90  -4.10  
(-5.08 to -3.11) 
 
 Comprehension 5.50  -4.500  
(-6.08 to -2.92) 
 
 Information 7.69  -2.31  
(-3.82 to -0.80)  
 
Perceptual Reasoning 93.74 94.54 -6.26 (-12.69 to 0.17) 
t(30)=-1.987 
0.056 
 Block Design 9.45  -0.55  
(-1.98 to 0.88) 
 
 Matrix 
Reasoning 
8.23  -1.77 
(-2.94 to 0.60) 
 
 Picture 
Concepts 
7.67  -2.33 
(-3.84 to -0.83) 
 
 Visual Puzzles 11.69  1.69 
(-0.27 to 3.66) 
 
Working Memory 80.23 80.09 -19.77 
(-25.00 to -14.55) 
t(30)=-7.730 
<0.0001 
 Digit Span 6.19  -3.81  
(-4.85 to -2.77)  
 
 Letter Number 
Sequences 
6.78  -3.22  
(-4.73 to -1.71) 
 
 Arithmetic 7.23  -2.769  
(-4.63 to -0.90)  
 
Processing Speed 83.13 82.90 -16.87 
(-22.24 to -11.50) 
t(30)=-6.413 
<0.0001 
 Coding 6.45   -3.55  
(-4.69 to -2.40) 
 
 Symbol Search 7.35   -2.65  
(-3.75 to -1.54) 
 
Full Scale IQ 80.45 80.89 - 19.55 
(-24.94 to -14.15) 
t(30)=-7.398 
<0.0001 
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Figure 1. IQ index score classifications for the FVS and normative comparison group*.  
*Normative comparison group distribution taken from Wechsler manual and applies to all indexes
(11,12)
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Highlights 
 
 Individuals with a diagnosis of fetal valproate syndrome demonstrated a higher 
frequency of intellectual difficulties. 
 Rates of IQ performance within the extremely low range were higher than those 
reported previously from non-clinical cohorts. 
 Verbal reasoning abilities were disproportionately impacted upon when compared to 
non-verbal reasoning. 
 Individuals without a major congenital malformation still demonstrated poorer 
intellectual ability.  
 Individuals with the valproate associated dysmorphic facial presentation should be 
reviewed by a neuropsychologist.   
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